Skip to main content
main-content

The American Diabetes Association | Virtual Scientific Sessions

12 JUNE – 16 JUNE

Top stories

Expert interviews

24-06-2020 | ADA 2020 | Conference coverage | Article

ADA 2020 goes virtual! Editorial Board conference highlights

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

23-06-2020 | ADA 2020 | Podcast | Article

Expert commentary: Closed-loop insulin delivery research update

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

18-06-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: The VERTIS-CV trial

Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).

16-06-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: The VERTIS-CV trial

Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).

15-06-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: Putting telehealth into practice for type 2 diabetes

Matthew Crowley discusses the successful implementation of a telehealth service for rural people with type 2 diabetes in clinical practice and its relevance to the current pandemic (13:07).

16-06-2020 | ADA 2020 | Conference coverage

Expert commentary: Could SGLT2 inhibition protect the liver in type 2 diabetes?

John Wilding discusses preliminary evidence that SGLT2 inhibition may counteract the adverse effects of type 2 diabetes on the liver (3:10).

14-06-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: Icosapent ethyl lowers cardiovascular risk in people with diabetes

Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).

Latest research news

24-06-2020 | ADA 2020 | Conference coverage | News

More studies show potential for slowing type 1 diabetes progression

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

23-06-2020 | ADA 2020 | Conference coverage | News

​​​​​​​CGM predictive low glucose alerts may prevent rebound hyperglycemia

Predictive low glucose alerts are associated with a reduced frequency and severity of rebound hyperglycemia among people using real-time continuous glucose monitoring, show study findings presented at the virtual ADA 80th Scientific Sessions.

17-06-2020 | ADA 2020 | Conference coverage | News

​​​​​​​Support for insulin degludec use in type 1 diabetes patients prone to nocturnal hypoglycemia

Findings from the HypoDeg trial suggest that insulin degludec is associated with a lower risk for hypoglycemia than insulin glargine U100 among people with type 1 diabetes who are prone to nocturnal severe hypoglycemia.

16-06-2020 | ADA 2020 | Conference coverage | News

Dapagliflozin may help prevent type 2 diabetes

15-06-2020 | ADA 2020 | Conference coverage | News

Evidence for liver benefits with SGLT2 inhibition


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits